Real-World Data Confirm Immunotherapy Boost for Aggressive Early Breast Cancer
A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery delivers event-free ...
A real-world study of 95 patients in Tokyo confirms that pembrolizumab combined with chemotherapy before and after surgery delivers event-free ...
A 15-year analysis of 454 herbal medicine adverse event reports at a Korean integrative medical center shows that nearly a ...
A propensity-matched analysis of nearly 20,000 patients reveals that aggressive diffuse large B-cell lymphoma carries a higher risk of acute ...
A new letter to the editor in the Journal of General Internal Medicine critically examines real-world evidence on insulin glargine ...
A new retrospective study by Stony Brook University researchers uses the TriNetX real-world data network to estimate how many Americans ...
A German analysis of insurance billing and nationwide hospital data finds that CAR-T therapy for diffuse large B-cell lymphoma carries ...
A real-world time-series analysis published in the Journal of General Internal Medicine finds that the first biosimilar insulin glargine did ...
A University of Minnesota study found that a hybrid open-source OCR pipeline extracted Oncotype DX breast cancer recurrence scores from ...
A new review in eClinicalMedicine shows how sarcoma trials can guide the implementation of the 2024 WHO guidance and ICH ...
A 12-year Japanese database study of 16,573 patients shows first-line nivolumab plus chemotherapy rapidly displaced cisplatin-based regimens in HER2-negative advanced ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine